Published in J Virol on December 01, 1992
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
Efficiency and selectivity of RNA packaging by Rous sarcoma virus Gag deletion mutants. J Virol (1994) 1.70
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
In vitro cell-free conversion of noninfectious Moloney retrovirus particles to an infectious form by the addition of the vesicular stomatitis virus surrogate envelope G protein. J Virol (1998) 1.26
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Conserved and variable features of Gag structure and arrangement in immature retrovirus particles. J Virol (2010) 1.09
Identification of the protease cleavage sites in a reconstituted Gag polyprotein of an HERV-K(HML-2) element. Retrovirology (2011) 0.92
The Mason-Pfizer monkey virus internal scaffold domain enables in vitro assembly of human immunodeficiency virus type 1 Gag. J Virol (2002) 0.92
Higher-order structure of the Rous sarcoma virus SP assembly domain. J Virol (2014) 0.89
Effect of dimerizing domains and basic residues on in vitro and in vivo assembly of Mason-Pfizer monkey virus and human immunodeficiency virus. J Virol (2009) 0.87
Conditional human immunodeficiency virus type 1 protease mutants show no role for the viral protease early in virus replication. J Virol (1996) 0.80
The noncanonical Gag domains p8 and n are critical for assembly and release of mouse mammary tumor virus. J Virol (2010) 0.80
Multimerization of the p12 domain is necessary for Mason-Pfizer monkey virus Gag assembly in vitro. Virology (2007) 0.80
Myristoylation drives dimerization of matrix protein from mouse mammary tumor virus. Retrovirology (2016) 0.75
DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci U S A (1977) 790.54
Rapid and efficient site-specific mutagenesis without phenotypic selection. Proc Natl Acad Sci U S A (1985) 68.48
High-efficiency transformation of mammalian cells by plasmid DNA. Mol Cell Biol (1987) 43.61
Eukaryotic transient-expression system based on recombinant vaccinia virus that synthesizes bacteriophage T7 RNA polymerase. Proc Natl Acad Sci U S A (1986) 32.58
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68
Complete nucleotide sequence of a milk-transmitted mouse mammary tumor virus: two frameshift suppression events are required for translation of gag and pol. J Virol (1987) 4.37
Replication and amplification of defective interfering particle RNAs of vesicular stomatitis virus in cells expressing viral proteins from vectors containing cloned cDNAs. J Virol (1990) 3.93
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70
Eukaryotic transient expression system dependent on transcription factors and regulatory DNA sequences of vaccinia virus. Proc Natl Acad Sci U S A (1985) 3.61
A new virus in a spontaneous mammary tumor of a rhesus monkey. Cancer Res (1970) 3.02
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
Isolation and propagation of a virus from a spontaneous mammary carcinoma of a rhesus monkey. Cancer Res (1970) 1.49
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Immunological cross reactivity of Mason-Pfizer monkey virus with type C RNA viruses endogenous to primates. Nature (1976) 1.37
Analysis of gag proteins from mouse mammary tumor virus. J Virol (1989) 1.27
Major structural proteins of type B, type C, and type D oncoviruses share interspecies antigenic determinants. Proc Natl Acad Sci U S A (1980) 1.18
Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst (1986) 1.11
Primate retroviruses: envelope glycoproteins of endogenous type C and type D viruses possess common interspecies antigenic determinants. J Virol (1978) 1.06
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol (2000) 6.71
Nucleotide sequence of Mason-Pfizer monkey virus: an immunosuppressive D-type retrovirus. Cell (1986) 6.07
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids. J Virol (1987) 5.68
A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc Natl Acad Sci U S A (1994) 4.43
Truncation of the human immunodeficiency virus type 1 transmembrane glycoprotein cytoplasmic domain blocks virus infectivity. J Virol (1992) 4.20
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus. Cell (1990) 3.70
A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J Virol (1998) 3.69
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Mutants of the Rous sarcoma virus envelope glycoprotein that lack the transmembrane anchor and cytoplasmic domains: analysis of intracellular transport and assembly into virions. J Virol (1987) 3.28
Human immunodeficiency virus envelope protein determines the site of virus release in polarized epithelial cells. Proc Natl Acad Sci U S A (1991) 3.18
Mutations of the Rous sarcoma virus env gene that affect the transport and subcellular location of the glycoprotein products. J Cell Biol (1984) 3.11
Oligomeric structure of a prototype retrovirus glycoprotein. Proc Natl Acad Sci U S A (1988) 3.06
Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc Natl Acad Sci U S A (1994) 2.88
Mutational analysis of the major homology region of Mason-Pfizer monkey virus by use of saturation mutagenesis. J Virol (1992) 2.56
Complete sequence of the Rous sarcoma virus env gene: identification of structural and functional regions of its product. J Virol (1983) 2.53
Amino acid substitutions within the matrix protein of type D retroviruses affect assembly, transport and membrane association of a capsid. EMBO J (1991) 2.51
Preassembled capsids of type D retroviruses contain a signal sufficient for targeting specifically to the plasma membrane. J Virol (1990) 2.51
Amino acids encoded downstream of gag are not required by Rous sarcoma virus protease during gag-mediated assembly. J Virol (1991) 2.38
Structural role of the matrix protein of type D retroviruses in gag polyprotein stability and capsid assembly. J Virol (1990) 2.34
Functional RT and IN incorporated into HIV-1 particles independently of the Gag/Pol precursor protein. EMBO J (1997) 2.23
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein that block processing to gp85 and gp37. J Virol (1987) 2.07
Truncations of the simian immunodeficiency virus transmembrane protein confer expanded virus host range by removing a block to virus entry into cells. J Virol (1993) 1.99
Postassembly cleavage of a retroviral glycoprotein cytoplasmic domain removes a necessary incorporation signal and activates fusion activity. J Virol (1994) 1.97
Role of the membrane-proximal domain in the initial stages of human immunodeficiency virus type 1 envelope glycoprotein-mediated membrane fusion. J Virol (1999) 1.89
Synthesis and assembly of retrovirus Gag precursors into immature capsids in vitro. J Virol (1996) 1.85
Polypeptides of Mason-Pfizer monkey virus. I. Synthesis and processing of the gag-gene products. Virology (1984) 1.83
A viral protease-mediated cleavage of the transmembrane glycoprotein of Mason-Pfizer monkey virus can be suppressed by mutations within the matrix protein. Proc Natl Acad Sci U S A (1992) 1.83
Efficient in vivo and in vitro assembly of retroviral capsids from Gag precursor proteins expressed in bacteria. J Virol (1995) 1.81
A chimeric avian retrovirus containing the influenza virus hemagglutinin gene has an expanded host range. J Virol (1992) 1.80
Distinct subsets of retroviruses encode dUTPase. J Virol (1992) 1.80
Avian reticuloendotheliosis viruses: evolutionary linkage with mammalian type C retroviruses. J Virol (1979) 1.68
The mechanism for genetic recombination in the avian retroviruses. Curr Top Microbiol Immunol (1978) 1.67
Biological techniques for avian sarcoma viruses. Methods Enzymol (1979) 1.67
Analysis of the cleavage site of the human immunodeficiency virus type 1 glycoprotein: requirement of precursor cleavage for glycoprotein incorporation. J Virol (1995) 1.54
A charged amino acid substitution within the transmembrane anchor of the Rous sarcoma virus envelope glycoprotein affects surface expression but not intracellular transport. J Cell Biol (1987) 1.50
Mutations within the proteolytic cleavage site of the Rous sarcoma virus glycoprotein define a requirement for dibasic residues for intracellular cleavage. J Virol (1992) 1.50
Expression and characterization of glycophospholipid-anchored human immunodeficiency virus type 1 envelope glycoproteins. J Virol (1993) 1.47
Effect of retroviral proteinase inhibitors on Mason-Pfizer monkey virus maturation and transmembrane glycoprotein cleavage. J Virol (1992) 1.46
Amino-terminal amino acid sequence of the major structural polypeptides of avian retroviruses: sequence homology between reticuloendotheliosis virus p30 and p30s of mammalian retroviruses. Proc Natl Acad Sci U S A (1978) 1.46
AIDS biosafety. Science (1991) 1.44
Pausing of reverse transcriptase on retroviral RNA templates is influenced by secondary structures both 5' and 3' of the catalytic site. Nucleic Acids Res (1998) 1.43
Inhibition of Rous sarcoma virus replication by 2-deoxyglucose and tunicamycin: identification of an unglycosylated env gene product. J Virol (1979) 1.42
Functional analysis of the core human immunodeficiency virus type 1 packaging signal in a permissive cell line. J Virol (1998) 1.38
Oligomerization of the hydrophobic heptad repeat of gp41. J Virol (1995) 1.38
Effect of cloned human interferons on protein synthesis and morphogenesis of herpes simplex virus. J Virol (1985) 1.38
Human immunodeficiency virus type 1 envelope glycoprotein is modified by O-linked oligosaccharides. J Virol (1994) 1.35
V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology (1992) 1.35
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein. J Virol (1999) 1.33
An avian sarcoma virus mutant that is temperature sensitive for virion assembly. Virology (1976) 1.33
Alterations in the transport and processing of Rous sarcoma virus envelope glycoproteins mutated in the signal and anchor regions. J Cell Biochem (1983) 1.31
Type D retrovirus capsid assembly and release are active events requiring ATP. J Virol (1998) 1.22
Amino-terminal deletion mutants of the Rous sarcoma virus glycoprotein do not block signal peptide cleavage but can block intracellular transport. J Cell Biol (1986) 1.21
Mutational analysis of conserved domains within the cytoplasmic tail of gp41 from human immunodeficiency virus type 1: effects on glycoprotein incorporation and infectivity. J Virol (2000) 1.21
Molecular cloning of the wild-type phoM operon in Escherichia coli K-12. J Bacteriol (1988) 1.20
A rapid screening procedure for the isolation of nonconditional replication mutants of Mason-Pfizer monkey virus: identification of a mutant defective in pol. Virology (1985) 1.19
Expression of the Rous sarcoma virus env gene from a simian virus 40 late-region replacement vector: effects of upstream initiation codons. J Virol (1987) 1.18
Alignment of the peptides derived from acid-catalyzed cleavage of an aspartylprolyl bond in the major internal structural polypeptide of avian retroviruses. J Biol Chem (1980) 1.17
Molecular events in the assembly of retrovirus particles. Adv Exp Med Biol (1998) 1.16
T lymphocyte cytotoxicity with natural varicella-zoster virus infection and after immunization with live attenuated varicella vaccine. J Immunol (1989) 1.15
Type D retrovirus Gag polyprotein interacts with the cytosolic chaperonin TRiC. J Virol (2001) 1.14
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus. J Virol (1999) 1.13
Can otolith elemental chemistry retrospectively track migrations in fully marine fishes? J Fish Biol (2012) 1.12
Mutations within the env gene of Mason-Pfizer monkey virus: effects on protein transport and SU-TM association. J Virol (1992) 1.12
Immunodeficiency in rhesus monkeys associated with the original Mason-Pfizer monkey virus. J Natl Cancer Inst (1986) 1.11
Health-related behaviours as predictors of mortality and morbidity in Australian Aborigines. Prev Med (2006) 1.09
Palmitoylation of the Rous sarcoma virus transmembrane glycoprotein is required for protein stability and virus infectivity. J Virol (2001) 1.09
Secondary structure model of the Mason-Pfizer monkey virus 5' leader sequence: identification of a structural motif common to a variety of retroviruses. J Virol (1995) 1.09
Polypeptides of Mason-Pfizer monkey virus. II. Synthesis and processing of the env gene products. Virology (1986) 1.09
Production and purification of a recombinant elastomeric polypeptide, G-(VPGVG)19-VPGV, from Escherichia coli. Biotechnol Prog (1992) 1.08
Inhibition of avian sarcoma virus replication by glucosamine. Virology (1974) 1.08
Molecular cloning of the Mason-Pfizer monkey virus genome: characterization and cloning of subgenomic fragments. Virology (1985) 1.08
Analysis of Mason-Pfizer monkey virus Gag particles by scanning transmission electron microscopy. J Virol (2001) 1.07
Social-cultural aspects of epilepsy in Kilimanjaro Region, Tanzania: knowledge and experience among patients and carers. Epilepsy Behav (2011) 1.07
Interferon inhibits Sendai virus-induced cell fusion: an effect on cell membrane fluidity. Proc Natl Acad Sci U S A (1982) 1.07
Analysis of retroviral assembly using a vaccinia/T7-polymerase complementation system. Virology (1993) 1.06
Transport of membrane proteins to the cell surface. Curr Top Microbiol Immunol (1991) 1.06
Analysis of Mason-Pfizer monkey virus Gag domains required for capsid assembly in bacteria: role of the N-terminal proline residue of CA in directing particle shape. J Virol (2000) 1.06
Retention of the human immunodeficiency virus type 1 envelope glycoprotein in the endoplasmic reticulum does not redirect virus assembly from the plasma membrane. J Virol (1998) 1.05
Amino-terminal amino acid sequence of p10, the fifth major gag polypeptide of avian sarcoma and leukemia viruses. J Virol (1983) 1.04
Polypeptides of Mason-Pfizer monkey virus. III. Translational order of proteins on the gag and env gene specified precursor polypeptides. Virology (1986) 1.03
Effect of monensin on Mason-Pfizer monkey virus glycoprotein synthesis. J Virol (1982) 1.02
Three active forms of aspartic proteinase from Mason-Pfizer monkey virus. Virology (1998) 1.01
Mutations within the transmembrane glycoprotein of Mason-Pfizer monkey virus: loss of SU-TM association and effects on infectivity. Virology (1994) 1.01
Inhibition of avian sarcoma virus replication by glucosamine: a specific effect on the synthesis and processing of viral proteins. Virology (1976) 1.00
Calmodulin and HIV type 1: interactions with Gag and Gag products. AIDS Res Hum Retroviruses (2000) 1.00
Integration of ambulance staff trained in cardiopulmonary resuscitation with a medical team providing prehospital coronary care. Br Heart J (1989) 0.99